US 10167337
Combination immunotherapy for the treatment of cancer
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10167337 (Combination immunotherapy for the treatment of cancer) held by The Board of Regents of the University of Texas System expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K38/1709, A61K39/3955